As more and more states enact drug pricing transparency reporting requirements, biopharma companies should effectively manage business impacts and address reputational and competitive vulnerabilities associated with increased transparency to avoid hefty penalties for noncompliance. This changing landscape means manufacturers should not only build stronger compliance and reporting operations supported by automation, but also enhance analytics to incorporate the impacts of state regulations on pricing strategy.